deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT04338022

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety (evolutionRMS 1)

Sponsor: EMD Serono Research & Development Institute, Inc.

Conditions Relapsing Multiple Sclerosis
Interventions Evobrutinib Teriflunomide
Updated 3 times since 2024 Last updated: May 26, 2025 Started: Jun 12, 2020 Primary completion: Oct 2, 2023 Completion: Mar 8, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Primary analysis of the RMS phase 3 study (MS200527\_0080) resulted in the early termination of the study.

Other terminated trials from EMD Serono Research & Development Institute, Inc.

More terminations from EMD Serono Research & Development Institute, Inc.

Other Relapsing Multiple Sclerosis trials with similar outcome

Browse all Relapsing Multiple Sclerosis trials

A PHASE3 clinical study on Relapsing Multiple Sclerosis, this trial is terminated or withdrawn. The trial is conducted by EMD Serono Research & Development Institute, Inc. and has accumulated 3 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Sep 2024 – ~Jul 2025 · 10 months · monthly snapshotTerminated~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshotTerminated~Sep 2025 – present · 8 months · monthly snapshotTerminated

Change History

3 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Jul 2025 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Sep 2024 — Jul 2025 [monthly]

    Terminated PHASE3

    First recorded

Jun 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • EMD Serono Research & Development Institute, Inc.
  • Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Data source: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aguascalientes, Mexico , Akron, United States , Alexandria, United States , Ashkelon, Israel , Auchenflower, Australia , Audubon, United States , Baltimore, United States , Bamberg, Germany , Barcelona, Spain , Barnaul, Russia and 208 more locations